Pharmacogenomics of oxcarbazepine in the treatment of epilepsy
Oxcarbazepine (OXC) is one of the preferred drugs for partial seizures and generalized tonic-clonic seizures. However, clinical studies have found that there are considerable differences among different populations in OXC therapeutic efficacy or safety that result from the function changes of metabolic enzymes, transporters and other receptors involved in pharmacokinetics and pharmacodynamics in vivo. The authors collected all the information on the clinically reported associations between variants of common genes (e.g., UGT1A9, HLA-B, ABCB1) and OXC. In conclusion, these associations based on variants are beneficial for adjusting the medication regimen, which could be useful for individualized treatment with OXC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 24(2023), 6 vom: 15. Apr., Seite 335-343 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yuan, Yujie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
33CM23913M |
|---|
| Anmerkungen: |
Date Completed 31.05.2023 Date Revised 01.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs-2022-0177 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355960524 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355960524 | ||
| 003 | DE-627 | ||
| 005 | 20231226065442.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2022-0177 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM355960524 | ||
| 035 | |a (NLM)37092337 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yuan, Yujie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacogenomics of oxcarbazepine in the treatment of epilepsy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.05.2023 | ||
| 500 | |a Date Revised 01.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Oxcarbazepine (OXC) is one of the preferred drugs for partial seizures and generalized tonic-clonic seizures. However, clinical studies have found that there are considerable differences among different populations in OXC therapeutic efficacy or safety that result from the function changes of metabolic enzymes, transporters and other receptors involved in pharmacokinetics and pharmacodynamics in vivo. The authors collected all the information on the clinically reported associations between variants of common genes (e.g., UGT1A9, HLA-B, ABCB1) and OXC. In conclusion, these associations based on variants are beneficial for adjusting the medication regimen, which could be useful for individualized treatment with OXC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a epilepsy | |
| 650 | 4 | |a genetic variants | |
| 650 | 4 | |a oxcarbazepine | |
| 650 | 4 | |a treatment efficacy | |
| 650 | 7 | |a Oxcarbazepine |2 NLM | |
| 650 | 7 | |a VZI5B1W380 |2 NLM | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Carbamazepine |2 NLM | |
| 650 | 7 | |a 33CM23913M |2 NLM | |
| 700 | 1 | |a Zhang, Shuang |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Yangyang |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Xinjing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Linlin |e verfasserin |4 aut | |
| 700 | 1 | |a Ran, Yun Wei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 24(2023), 6 vom: 15. Apr., Seite 335-343 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:6 |g day:15 |g month:04 |g pages:335-343 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2022-0177 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 6 |b 15 |c 04 |h 335-343 | ||